Widening the Neuroimaging Features of Adenosine Deaminase 2 Deficiency

References

1. 1.↵
   1. Navon Elkan P,
   2. Pierce SB,
   3. Segel R, et al

   . Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014;370:921–31 doi:10.1056/NEJMoa1307362 pmid:24552285

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Zhou Q,
   2. Yang D,
   3. Ombrello AK, et al

   . Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014;370:911–20 doi:10.1056/NEJMoa1307361 pmid:24552284

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Bras J,
   2. Guerreiro R,
   3. Santo GC

   . Mutant ADA2 in vasculopathies. N Engl J Med 2014;371:478–80 doi:10.1056/NEJMc1405506 pmid:25075847

   CrossRefPubMed
4. 4.↵
   1. Van Montfrans JM,
   2. Hartman EAR,
   3. Braun KPJ, et al

   . Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford) 2016;55:902–10 doi:10.1093/rheumatology/kev439 pmid:26867732

   CrossRefPubMed
5. 5.↵
   1. Lee PY,
   2. Kellner ES,
   3. Huang Y, et al

   . Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol 2020;145:1664–72.e10 doi:10.1016/j.jaci.2019.12.908 pmid:31945408

   CrossRefPubMed
6. 6.↵
   1. Fayand A,
   2. Sarrabay G,
   3. Belot A, et al

   . Multiple facets of ADA2 deficiency: vasculitis, auto-inflammatory disease and im-munodeficiency: a literature review of 135 cases from literature. Rev Med Interne 2018;39:297–306 doi:10.1016/j.revmed.2017.11.006 pmid:29273180

   CrossRefPubMed
7. 7.↵
   1. Westendorp WF,
   2. Nederkoorn PJ,
   3. Aksentijevich I, et al

   . Unexplained early-onset lacunar stroke and inflammatory skin lesions: consider ADA2 deficiency. Neurology 2015;84:2092–93 doi:10.1212/WNL.0000000000001581 pmid:25888558

   CrossRefPubMed
8. 8.↵
   1. Nanthapisal S,
   2. Murphy C,
   3. Omoyinmi E, et al

   . Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol 2016;68:2314–22 doi:10.1002/art.39699 pmid:27059682

   CrossRefPubMed
9. 9.↵
   1. Elbracht M,
   2. Mull M,
   3. Wagner N, et al

   . Stroke as initial manifestation of adenosine deaminase 2 deficiency. Neuropediatrics 2017;48:111–14 doi:10.1055/s-0036-1597611 pmid:28024309

   CrossRefPubMed
10. 10.↵
    1. Caorsi R,
    2. Penco F,
    3. Grossi A, et al

    . ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis 2017;76:1648–56 doi:10.1136/annrheumdis-2016-210802 pmid:28522451

    Abstract/FREE Full Text
11. 11.↵
    1. Özen S,
    2. Batu ED,
    3. Taşkiran EZ, et al

    . A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2. J Rheumatol 2020;47:117–25 doi:10.3899/jrheum.181384 pmid:31043544

    Abstract/FREE Full Text
12. 12.↵
    1. Sahin S,
    2. Adrovic A,
    3. Barut K, et al

    . Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency. Rheumatol Int 2018;38:129–36 doi:10.1007/s00296-017-3740-3 pmid:28516235

    CrossRefPubMed
13. 13.↵
    1. Caorsi R,
    2. Omenetti A,
    3. Morreale A, et al

    . Rapid and sustained effect of anti-TNF treatment in patients with ADA2 deficiency. Ped Rheumatol 2015;13:(Suppl) O80 doi:10.1186/1546-0096-13-S1-O80

    CrossRef
14. 14.↵
    1. Bulut E,
    2. Erden A,
    3. Karadag O, et al

    . Deficiency of adenosine deaminase 2; special focus on central nervous system imaging. J Neuroradiol 2019;46:193–98 doi:10.1016/j.neurad.2018.05.002 pmid:29913178

    CrossRefPubMed
15. 15.↵
    1. Ganhão S,
    2. Loureiro GB,
    3. Oliveira DR, et al

    . Two cases of ADA2 deficiency presenting as childhood polyarteritis nodosa: novel ADA2 variant, atypical CNS manifestations, and literature review. Clin Rheumatol 2020;39:3853–60 doi:10.1007/s10067-020-05210-4 pmid:32535845

    CrossRefPubMed
16. 16.↵
    1. Toyoda K,
    2. Tsutsumi K,
    3. Hirao T, et al

    . Ruptured intracranial aneurysms in pediatric polyarteritis nodosa. Neurol Med Chir (Tokyo) 2012;52:928–932 doi:10.2176/nmc.52.928 pmid:23269053

    CrossRefPubMed
17. 17.↵
    1. Boukobza M,
    2. Dossier A,
    3. Laissy JP

    . Thrombosed aneurysm of the posterior inferior cerebellar artery and lateral medullary ischemia as the initial presentation of polyarteritis nodosa: case report and literature review. J Stroke Cerebrovasc Dis 2018;27:e168–71 doi:10.1016/j.jstrokecerebrovasdis.2018.02.061 pmid:29602618

    CrossRefPubMed
18. 18.↵
    1. Smith G,
    2. Hoh BL,
    3. Albayram MS

    . Anterior spinal artery aneurysm presenting with spinal subarachnoid hemorrhage in a case of polyarteritis nodosa. Clin Imaging 2019;56:108–13 doi:10.1016/j.clinimag.2019.04.008 pmid:31029009

    CrossRefPubMed
19. 19.↵
    1. Wardlaw JM,
    2. Smith C,
    3. Dichgans M

    . Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol 2013;12:483–97 doi:10.1016/S1474-4422(13)70060-7 pmid:23602162

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Mandell DM,
    2. Mossa-Basha M,
    3. Qiao Y, et al

    . Intracranial vessel wall MRI: principles and expert consensus recommendations of the American Society of Neuroradiology. AJNR Am J Neuroradiol 2017;38:218–29 doi:10.3174/ajnr.A4893 pmid:27469212

    Abstract/FREE Full Text
21. 21.↵
    1. Garg N,
    2. Kasapcopur O,
    3. Foster J, et al

    . Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr 2014;173:827–30 doi:10.1007/s00431-014-2320-8 pmid:24737293

    CrossRefPubMed
22. 22.↵
    1. Navinan MR,
    2. Subasinghe CJ,
    3. Kandeepan T, et al

    . Polyarteritis nodosa complicated by posterior reversible encephalopathy syndrome: a case report. BMC Res Notes 2014;7:89 doi:10.1186/1756-0500-7-89 pmid:24529495

    CrossRefPubMed
23. 23.↵
    1. Fugate JE,
    2. Rabinstein AA

    . Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 2015;14:914–25 doi:10.1016/S1474-4422(15)00111-8 pmid:26184985

    CrossRefPubMed